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Abstract
This Brief Communication represents an analysis of the cost savings to MaineCare (also referred to as Medicaid) directly 
attributable to service provided via speech therapy telepractice. Seven female (primarily adolescent) MaineCare patients 
consecutively referred to Waldo County General Hospital (WCGH) with suspected diagnosis of Vocal Cord Dysfunction 
(VCD) were treated by speech therapy telepractice. Outcome data demonstrated a first month cost savings of $2376.72. 
The analysis additionally projected thousands of dollars of potential savings each month in reduced medical costs for this 
patient group as a result of successful treatment via speech therapy telepractice.  The study suggests that without access 
to speech therapy telepractice for patients with VCD, the medical costs to MaineCare will be ongoing and significant.
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Background/Rationale
The efficacy of telemedicine and telerehabilitation in 
treating medical disorders has been established for more 
than 20 years. The direct cost benefits are now being 
recognized on a federal level, with CMS Medicaid stating: 
“Telemedicine is viewed as a cost-effective alternative to 
the more traditional face-to-face way of providing medical 
care” (Centers for Medicare & Medicaid Services, 2012). 
This Brief Communication represents an analysis of the 
cost savings to MaineCare (also referred to as Medicaid) 
directly attributable to service provided via speech 
therapy telepractice for Vocal Cord Dysfunction (VCD) 
by telepractitioners at Waldo County General Hospital 
(WCGH). WCGH recognizes the responsibility to provide 
high quality outcomes to all Maine citizens, via services 
that reduce the cost of health care delivery. The speech 
therapy department at WCGH has therefore created a 
model of service delivery that requires less treatment at 
less cost, while achieving outcomes that are equal to or 
exceed national benchmarks (WCGH, 2012). 
VCD, also termed Paradoxical Vocal Fold Motion 
(PVFM), was initially identified and described in 1983 by 
a multi-disciplinary team led by Kent Christopher, MD at 
National Jewish Hospital in Denver, CO. (Blager, 2006; 
2008). VCD is an abnormal spasm of the vocal folds and 
laryngeal system that blocks the airway and renders 
inhalation difficult or impossible. VCD can be triggered by 
exercise, odors, swallowing, stress, or a hypersensitive 
reaction of the throat to an irritation. This condition can 
create heightened anxiety and fear in patients, with 
many reporting that during a VCD episode, they thought 
they might die.  VCD most often affects women, with a 
subgroup of young female athletes who are affected.
It is not unusual for VCD to be undiagnosed for months 
and even years, resulting in high costs of unnecessary 
medication, diagnostic testing, and repeat physician office 
visits. VCD is often mistaken for asthma and treated with a 
standard course of medications and inhalers.   Emergency 
room visits often ensue when these patients are unable to 
breathe -- potentially triggering invasive procedures such 
as intubation or tracheostomy. 
Some VCD referrals are complex cases with no qualified 
provider in their communities; some have previously had 
failed treatment; and some have multiple associated 
medical diagnoses.  At WCGH/Speech Language 
Pathology, one woman was seen with a 43 year history of 
the disorder. Another patient was a young female athlete 
with a five year history of VCD following a near drowning 
event.  Another female athlete who presented with more 
than 100 emergency room and hospital admissions before 
being properly diagnosed and successfully treated.
The standard of practice for VCD is treatment by a 
speech-language pathologist (National Jewish Health, 
2012). When correctly diagnosed and properly treated, 
total symptom relief can be expected in 6-8 speech 
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therapy visits, and is often achieved in 1-4 visits by 
incorporating voice facilitation and vocal performance 
techniques (Ricker & Towey, 2007).
WCGH has developed specialized expertise in the 
treatment of this disorder and receives referrals from 
medical specialists throughout Maine for evaluation and 
treatment of VCD patients.  At WCGH, VCD patients are 
routinely treated in 2-4 visits. An initial onsite evaluation 
is completed that includes endoscopic visualization of 
laryngeal positioning. The examination incorporates 
environmental challenges to induce symptoms. Follow-up 
treatment is most typically by speech therapy telepractice 
due to barriers of long travel distances for return visits, 
access to qualified providers, and the effectiveness of 
speech therapy telepractice. 
The correct treatment for VCD results in reduced use 
of or elimination of medications; reduced physician 
office and emergency room visits; and reduced costs in 
diagnostic medical procedures. When properly managed, 




Consecutive MaineCare patients referred to speech 
therapy at WCGH were selected for retrospective review, 
all diagnosed with the same disorder (VCD). Prior to 
referral/treatment, all patients had sustained ongoing 
costs to MaineCare for treatment of symptoms.  
The independent variable in the successful treatment 
outcomes for all these MaineCare patients was access 
to skilled speech therapy and telepractice.  The patients 
were offered the option of a return in-person visit to 
the WCGH speech therapy department. All refused 
in-office treatment due to distance, cost of travel, time 
involved in travel, caregiver burden or difficulty arranging 
transportation. Instead, the seven patients selected 
treatment by speech therapy telepractice. 
Study Group: 
The group (summarized in Table 2) of consecutive 
MaineCare patients diagnosed with VCD lived an average 
of 67 miles from WCGH (range: 14-143 miles). All were 
females with a mean age of 17.4 years (range 11-38 years). 
Onset of symptoms ranged from five years to several 
months. All had been treated with standard procedures 
of medications, repeat office visits, and emergency room 
visits. Some had failed to improve with previous traditional 
therapy approaches.
Results:
Seven consecutive MaineCare patients with a diagnosis 
of Vocal Cord Dysfunction (VCD) were treated by speech 
therapy telepractice at a cost of $667.94 to MaineCare 
(MaineCare provider rate). (Table 1)   Treatment resulted 
in successful outcomes for the entire group. Further 
medical tests were canceled, related medications were 
discontinued, and repeat physician and emergency room 
visits for treatment of symptoms were eliminated.
Table 1
In contrast, in the month prior to referral to the 
WCGH speech therapy department for evaluation and 
treatment, MaineCare was responsible for $3035.16 in 
medical expenses for this group. Based upon the costs 
related to this condition accrued in the month preceding 
telepractice, the first month cost savings to MaineCare 
was $2376.72 (Table 1), a 72% cost reduction. These 
savings would not have been possible without access to 
speech therapy telepractice.  
Monthly MaineCare Costs & Savings Speech Therapy Telemedicine 
Cost    Cost    Savings
Before  telepractice Speech telepractice One Month
$3035.66   $667.94   $2367.72
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As shown in Table 2, the eliminated expenses included 
physician office visits, emergency room visits, planned 
medical evaluations, and prescription medications. 
Telepractice therefore eliminated the need for repeat 
expensive medical encounters, (e.g., emergency room 
visits; Methacholine or bronchial challenges; pulmonary 
function testing (PFT)) and medication use (e.g., Albuterol; 
Flovent; ProAir HFA 108).
These outcomes have produced ongoing savings to 
MaineCare in the range of $2300 to $3000 per month. 
Patients remained symptom free at the one-year follow-up 
by phone interview. 
Without the telepractice interventions, MaineCare 
would continue to accrue thousands of dollars in ongoing 
monthly medical costs until these patients are effectively 









                 History 
 








Onset six months prior.  
Pulmonary Function Test (PFT). 
No asthma. 
Two speech therapy telepractice 
visits.  
Symptoms resolved. 







Intermittent, several years. 
Pediatrician referral; considering 
PFT. 




Order for PFT methacholine 







History of gastroesophageal 
reflux disease (GERD) w/Nissan 
Fundoplication, VCD, asthma. 
Anxiety, twice monthly ER visits. 
Four treatments, two/office, 
two/speech therapy telepractice 
visits. 
Symptoms resolved. 







Multiple episodes of VCD; 
GERD. Repeated ER visits. 
Albuterol.  
Previous therapy did not help 




PFT normal.  
ProAir HFA 108 
discontinued. 
Eliminated one time monthly 





73 miles  
VCD, cough symptoms 4-5 
years. 
One speech therapy telepractice 
visit.  
 
No repeat symptoms. 
Eliminated repeat PCP visits 






VCD, periods of aphonic onset 
(one year), repeated primary 
care physician (PCP) visits for 
symptoms. 
One speech therapy telepractice 
visit.  
 
Symptoms fully resolved. 









Pre treats with inhaler before 
exercise and during episodes. 
Intense throat clearing/coughing 
resulting in recurrent PCP visits. 




Discontinued Pro Air inhaler 
use. 
Challenged with variety of 
noxious elements, with no 
response.  




Cost Basis:  
 
Walgreens pharmacy (Maine, 2011): Flovent $197.99; Albuterol $10.99; ProAir HFA 108: $59.99 
 
WCGH: Pulmonary Function Test (PFT): $299.00; Methacholine challenge: $607.10; Emergency Room visit: $500.00 
(minimum); MD office visit: $60 (minimum). 
 
Table 2
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Conclusions
Lack of qualified provider in their home communities, 
failed previous treatment and low economic status/limited 
transportation had resulted in increased costs of medical 
care to MaineCare for seven patients with suspected 
Vocal Fold Dysfunction (VCD). VCD is a condition 
characterized by an abnormal spasm of the vocal folds 
and laryngeal system that blocks the airway and renders 
inhalation difficult or impossible.
Without access to the treatment provided by speech 
therapy telepractice, these patients would have continued 
to experience chronic symptoms resulting in costly and 
unnecessary medical care. The nature of the disorder is 
that VCD symptoms (and the associated medical costs) 
would have continued for months or years. This is the 
consistent pattern observed at WCGH in more than 100 
clinical cases over the last five years. 
Due to geographic isolation, lack of providers, and 
limited access to transportation, it is not likely these 
patients could have returned to WCGH for speech therapy 
treatment. If some return visits to WCGH could have 
been completed, there would have been additional costs 
to MaineCare in paying for required transportation to a 
medical appointment.
Vocal Fold Dysfunction (VCD) is just one of a host of 
preventable and/or treatable conditions for which the use 
of telepractice might result in significant cost-savings 
for patients (e.g., reduced costs for transportation, 
caregivers, and/or lost income), insurers, and society. It 
is incumbent upon telepractioners to identify other such 
conditions, and demonstrate the potential savings. 
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